175 related articles for article (PubMed ID: 33550518)
1. Geographic impact on access to care and survival for non-curative esophagogastric cancer: a population-based study.
Yee EK; Coburn NG; Zuk V; Davis LE; Mahar AL; Liu Y; Gupta V; Darling G; Hallet J
Gastric Cancer; 2021 Jul; 24(4):790-799. PubMed ID: 33550518
[TBL] [Abstract][Full Text] [Related]
2. Impact of Geography on Care Delivery and Survival for Noncurable Pancreatic Adenocarcinoma: A Population-Based Analysis.
Yee EK; Coburn NG; Davis LE; Mahar AL; Zuk V; Gupta V; Liu Y; Earle CC; Hallet J
J Natl Compr Canc Netw; 2020 Dec; 18(12):1642-1650. PubMed ID: 33285520
[TBL] [Abstract][Full Text] [Related]
3. Variation in receipt of therapy and survival with provider volume for medical oncology in non-curative esophago-gastric cancer: a population-based analysis.
Hallet J; Davis LE; Mahar AL; Liu Y; Zuk V; Gupta V; Earle CC; Coburn NG
Gastric Cancer; 2020 Mar; 23(2):300-309. PubMed ID: 31628561
[TBL] [Abstract][Full Text] [Related]
4. Patterns of surveillance following curative intent therapy for gastroesophageal cancer.
Peixoto RD; Lim HJ; Kim H; Abdullah A; Cheung WY
J Gastrointest Cancer; 2014 Sep; 45(3):325-33. PubMed ID: 24756830
[TBL] [Abstract][Full Text] [Related]
5. Economic impacts of care by high-volume providers for non-curative esophagogastric cancer: a population-based analysis.
Hallet J; Look Hong NJ; Zuk V; Davis LE; Gupta V; Earle CC; Mittmann N; Coburn NG
Gastric Cancer; 2020 May; 23(3):373-381. PubMed ID: 31834527
[TBL] [Abstract][Full Text] [Related]
6. A retrospective cohort study of patients with stomach and liver cancers: the impact of comorbidity and ethnicity on cancer care and outcomes.
Sarfati D; Gurney J; Stanley J; Koea J
BMC Cancer; 2014 Nov; 14():821. PubMed ID: 25380581
[TBL] [Abstract][Full Text] [Related]
7. Access to chemotherapy services by availability of local and visiting oncologists.
Ward MM; Ullrich F; Matthews K; Rushton G; Tracy R; Bajorin DF; Goldstein MA; Kosty MP; Bruinooge SS; Hanley A; Lynch CF
J Oncol Pract; 2014 Jan; 10(1):26-31. PubMed ID: 24443731
[TBL] [Abstract][Full Text] [Related]
8. Geographical differences in cancer treatment and survival for patients with oesophageal and gastro-oesophageal junctional cancers.
Jestin Hannan C; Linder G; Kung CH; Johansson J; Lindblad M; Hedberg J
Br J Surg; 2020 Oct; 107(11):1500-1509. PubMed ID: 32484241
[TBL] [Abstract][Full Text] [Related]
9. Low rates of specialized cancer consultation and cancer-directed therapy for noncurable pancreatic adenocarcinoma: a population-based analysis.
Mavros MN; Coburn NG; Davis LE; Mahar AL; Liu Y; Beyfuss K; Myrehaug S; Earle CC; Hallet J
CMAJ; 2019 May; 191(21):E574-E580. PubMed ID: 31133604
[TBL] [Abstract][Full Text] [Related]
10. Does chemoradiotherapy improve outcomes for surgically resected adenocarcinoma of the stomach or esophagus?
Solomon NL; Cheung MC; Byrne MM; Zhuge Y; Franceschi D; Livingstone AS; Koniaris LG
Ann Surg Oncol; 2010 Jan; 17(1):98-108. PubMed ID: 19777191
[TBL] [Abstract][Full Text] [Related]
11. Early Interdisciplinary Supportive Care in Patients With Previously Untreated Metastatic Esophagogastric Cancer: A Phase III Randomized Controlled Trial.
Lu Z; Fang Y; Liu C; Zhang X; Xin X; He Y; Cao Y; Jiao X; Sun T; Pang Y; Wang Y; Zhou J; Qi C; Gong J; Wang X; Li J; Tang L; Shen L
J Clin Oncol; 2021 Mar; 39(7):748-756. PubMed ID: 33417481
[TBL] [Abstract][Full Text] [Related]
12. Association Between Geographic Access to Cancer Care, Insurance, and Receipt of Chemotherapy: Geographic Distribution of Oncologists and Travel Distance.
Lin CC; Bruinooge SS; Kirkwood MK; Olsen C; Jemal A; Bajorin D; Giordano SH; Goldstein M; Guadagnolo BA; Kosty M; Hopkins S; Yu JB; Arnone A; Hanley A; Stevens S; Hershman DL
J Clin Oncol; 2015 Oct; 33(28):3177-85. PubMed ID: 26304878
[TBL] [Abstract][Full Text] [Related]
13. Is patient travel distance associated with survival on phase II clinical trials in oncology?
Lamont EB; Hayreh D; Pickett KE; Dignam JJ; List MA; Stenson KM; Haraf DJ; Brockstein BE; Sellergren SA; Vokes EE
J Natl Cancer Inst; 2003 Sep; 95(18):1370-5. PubMed ID: 13130112
[TBL] [Abstract][Full Text] [Related]
14. First-Line Palliative Chemotherapy for Esophageal and Gastric Cancer: Practice Patterns and Outcomes in the General Population.
Merchant SJ; Kong W; Gyawali B; Hanna TP; Chung W; Nanji S; Patel SV; Booth CM
JCO Oncol Pract; 2021 Oct; 17(10):e1537-e1550. PubMed ID: 33449833
[TBL] [Abstract][Full Text] [Related]
15. The role of adjuvant platinum-based chemotherapy in esophagogastric cancer patients who received neoadjuvant chemotherapy prior to definitive surgery.
Saunders JH; Bowman CR; Reece-Smith AM; Pang V; Dorrington MS; Mumtaz E; Soomro I; Kaye P; Madhusudan S; Parsons SL
J Surg Oncol; 2017 Jun; 115(7):821-829. PubMed ID: 28257148
[TBL] [Abstract][Full Text] [Related]
16. Patient education-level affects treatment allocation and prognosis in esophageal- and gastroesophageal junctional cancer in Sweden.
Linder G; Sandin F; Johansson J; Lindblad M; Lundell L; Hedberg J
Cancer Epidemiol; 2018 Feb; 52():91-98. PubMed ID: 29278841
[TBL] [Abstract][Full Text] [Related]
17. Determinants of the access to remote specialised services provided by national sarcoma reference centres.
Fayet Y; Tétreau R; Honoré C; Le Nail LR; Dalban C; Gouin F; Causeret S; Piperno-Neumann S; Mathoulin-Pelissier S; Karanian M; Italiano A; Chaigneau L; Gantzer J; Bertucci F; Ropars M; Saada-Bouzid E; Cordoba A; Ruzic JC; Varatharajah S; Ducimetière F; Chabaud S; Dubray-Longeras P; Fiorenza F; De Percin S; Lebbé C; Soibinet P; Michelin P; Rios M; Farsi F; Penel N; Bompas E; Duffaud F; Chevreau C; Le Cesne A; Blay JY; Le Loarer F; Ray-Coquard I
BMC Cancer; 2021 May; 21(1):631. PubMed ID: 34049529
[TBL] [Abstract][Full Text] [Related]
18. Population-based study of the impact of surgical and adjuvant therapy at the same or a different institution on survival of patients with pancreatic adenocarcinoma.
Latchana N; Davis L; Coburn NG; Mahar A; Liu Y; Hammad A; Kagedan D; Elmi M; Siddiqui M; Earle CC; Hallet J
BJS Open; 2019 Feb; 3(1):85-94. PubMed ID: 30734019
[TBL] [Abstract][Full Text] [Related]
19. Perioperative chemo(radio)therapy versus primary surgery for resectable adenocarcinoma of the stomach, gastroesophageal junction, and lower esophagus.
Ronellenfitsch U; Schwarzbach M; Hofheinz R; Kienle P; Kieser M; Slanger TE; Jensen K;
Cochrane Database Syst Rev; 2013 May; (5):CD008107. PubMed ID: 23728671
[TBL] [Abstract][Full Text] [Related]
20. Real-World Outcomes and Factors Associated With the Second-Line Treatment of Patients With Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma.
Barzi A; Hess LM; Zhu YE; Liepa AM; Sugihara T; Beyrer J; Chao J
Cancer Control; 2019; 26(1):1073274819847642. PubMed ID: 31056940
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
